Covid: Sanofi’s second vaccine not to be ready in 2021

Published by Laurent P. · Published on 14 February 2021 at 15h47 · Updated on 15 February 2021 at 16h04
After announcing likely delay in the marketing of their Covid vaccine developed with GSK, Sanofi announced this Sunday February 14 that their second vaccine – developed in partnership with American biotech Translate Bio – is not likely to be ready in 2021. The announcement has been made by French pharmaceutical group director general Paul Hudson in an interview with JDD.

Another hard blow for Sanofi in the race for Covid vaccine… This Sunday February 14, the French laboratory director general, Paul Hudson, announced in an interview with Journal du Dimanche the pharmaceutical group’s second vaccine – being developed in partnership with American company Translate Bio – will not be released in 2021 as first expected.

But this vaccine “could be of use at a later stage all the more if the fight against variants was to continue” he explained. He detailed “this technology, developed with the biotech Translate Bio, with which we have been associated since 2018, has shown the production of high concentrations of antibodies in preclinical studies”.

This is a vaccine that uses – like Pfizer or Moderna – the mRNA technology. Clinical trials are to start this quarter. Please also note another vaccine designed by Sanofi – in partnership with GSK – has been delayed and is to be issued by the end of 2021 – if everything goes as scheduled. In the meantime, the French group has also stated that they will help competitor Pfizer manufacture more doses of their vaccine by rallying several production chains in Europe.

Practical information

Comments
Refine your search
Refine your search
Refine your search
Refine your search